Glenmark Pharma gains after JV submits IND application for cancer drug ISB 2301
Mumbai, Nov. 18 -- ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and NK cells. By combining tumor-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumors.
Ichnos Glenmark Innovation plans to initiate a Phase I clinical trial of ISB 2301 in patients with solid tumours in 2027.
Lida Pacaud, M.D., president and chief executive officer, IGI, said, "ubmission of the IND for ISB 2301 marks an important milestone in advancing IGI's multispecific oncology pipeline into clinical development, this pentaspecific candidate is design...
Click here to read full article from source
इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया
हमे संपर्क करें.